MG
ATRA icon

Michael Gelband’s Atara Biotherapeutics ATRA Stock Holding History

Michael Gelband’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,467
Closed -$720K – 1463
2023
Q3 		$720K Buy
19,467
+2,752
+16% +$122K 0.01% 1098
2023
Q2 		$673K Buy
16,715
+5,776
+53% +$327K 0.01% 1247
2023
Q1 		$793K Buy
10,939
+8,489
+346% +$823K 0.01% 1219
2022
Q4 		$201K Buy
2,450
+52
+2% +$5.42K ﹤0.01% 1459
2022
Q3 		$227K Buy
+2,398
New +$269K ﹤0.01% 1604
2021
Q3 		– Sell
-498
Closed -$193K – 2099
2021
Q2 		$193K Buy
+498
New +$178K ﹤0.01% 1997
2021
Q1 		– Sell
-1,110
Closed -$545K – 2108
2020
Q4 		$545K Buy
+1,110
New +$512K 0.01% 1191
2020
Q1 		– Sell
-498
Closed -$205K – 1076
2019
Q4 		$205K Buy
+498
New +$172K ﹤0.01% 1332

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Michael Gelband's ATRA Position: Q4 2023 in Review

Michael Gelband sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 19,467 shares — an estimated $720K sold.

Michael Gelband first reported a position in ATRA in Q4 2019 and held it in 8 quarters. The position peaked at $793K in Q1 2023. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • Michael Gelband reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Michael Gelband sold 19,467 Atara Biotherapeutics shares in Q4 2023, an estimated $720K.
  • Michael Gelband first reported a position in Atara Biotherapeutics in Q4 2019 and held it in 8 quarters.
  • Michael Gelband's Atara Biotherapeutics position peaked at $793K in Q1 2023.
  • 89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on ExodusPoint Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.